Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int Microbiol ; 26(4): 939-949, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36991248

RESUMEN

Recently, many efforts have been made to treat cancer using recombinant bacterial toxins and this strategy has been used in clinical trials of various cancers. Therapeutic DNA cancer vaccines are now considered as a promising strategy to activate the immune system against cancer. Cancer vaccines could induce specific and long-lasting immune responses against tumors. This study aimed to evaluate the antitumor potency of the SEB DNA vaccine as a new antitumor candidate against breast tumors in vivo. To determine the effect of the SEB construct on inhibiting tumor cell growth in vivo, the synthetic SEB gene, subsequent codon optimization, and embedding the cleavage sites were sub-cloned to an expression vector. Then, SEB construct, SEB, and PBS were injected into the mice. After being vaccinated, 4T1 cancer cells were injected subcutaneously into the right flank of mice. Then, the cytokine levels of IL-4 and IFN-γ were estimated by the ELISA method to evaluate the antitumor activity. The spleen lymphocyte proliferation, tumor size, and survival time were assessed. The concentration of IFN-γ in the SEB-Vac group showed a significant increase compared to other groups. The production of IL-4 in the group that received the DNA vaccine did not change significantly compared to the control group. The lymphocyte proliferation increased significantly in the mice group that received SEB construct than PBS control group (p < 0.001). While there was a meaningful decrease in tumor size (p < 0.001), a significant increase in tumor tissue necrosis (p < 0.01) and also in survival time of the animal model receiving the recombinant construct was observed. The designed SEB gene construct can be a new model vaccine for breast cancer because it effectively induces necrosis and produces specific immune responses. This structure does not hurt normal cells and is a safer treatment than chemotherapy and radiation therapy. Its slow and long-term release gently stimulates the immune system and cellular memory. It could be applied as a new model for inducing apoptosis and antitumor immunity to treat cancer.


Asunto(s)
Vacunas contra el Cáncer , Neoplasias , Vacunas de ADN , Ratones , Animales , Vacunas de ADN/genética , Modelos Animales de Enfermedad , Vacunas contra el Cáncer/genética , Interleucina-4 , Necrosis , Ratones Endogámicos BALB C
2.
J Cell Physiol ; 234(4): 4970-4986, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30216449

RESUMEN

BACKGROUND AND OBJECTIVES: Mesenchymal stem cells (MSCs)-based regenerative therapy is now considered as an alternative approach to revive infectious diseases, including sepsis. Nevertheless, the efficiency of MSC application is limited by the poor survival rate of engrafted MSCs. Hence, preconditioning was established as a strategy to increase the cells' efficiency. METHODS: MSCs were preconditioned with 1 µg/ml of three different lipopolysaccharides (LPSs) of Pseudomonas (Pse-LPS), Acinetobacter (Ac-LPS), and Acinetobacter inactivated lipid A by PagL (Ac-LPS-PagL). Then, preconditioned MSCs were exposed to oxidative stress and serum deprivation followed by evaluation of the antibacterial activity, survival, and apoptosis of MSCs. Then, the murine sepsis model treated with 100 µl phosphate-buffered saline (control group, sepsis group), 100 µl of 1 × 10 6 wild MSCs (MSC group), and three remained groups received 100 µl of 1 × 10 6 LPS-preconditioned MSCs (Pse-LPS-MSCs group: LPS purified from Pseudomonas, or Ac-LPS-MSCs group: LPS purified from Acinetobacter, and Ac-PagL-LPS-MSCs group: detoxified LPS Pagl). RESULTS: After 4 days, LPS-preconditioned MSC transplantation modulated the immune response and reduced inflammation in septic mice. Apoptosis of Pse-LPS/Ac-LPS-preconditioned-MSCs was obviously reduced in vitro, and the survival rate of engrafted mice was evidently elevated in Pse-LPS-MSCs and Ac-LPS-MSCs groups compared with other three groups. CONCLUSION: LPS preconditioning provides an innovative strategy for evolving functional and biological properties of MSCs and ameliorates the survival rate of the mouse model of sepsis after MSC transplantation, protects cells from apoptosis and organ damages, and evaluates therapeutic properties, including immunemodulatory.


Asunto(s)
Trasplante de Células Madre Mesenquimatosas/métodos , Células Madre Mesenquimatosas/metabolismo , Medicina Regenerativa/métodos , Sepsis/terapia , Acinetobacter baumannii/metabolismo , Animales , Carga Bacteriana , Modelos Animales de Enfermedad , Lipopolisacáridos/farmacología , Masculino , Ratones , Pseudomonas aeruginosa/metabolismo , Ratas , Ratas Sprague-Dawley , Sepsis/microbiología
3.
Cytotherapy ; 21(1): 41-53, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30477894

RESUMEN

Sepsis, a health-threatening progressive infectious disease, is the major cause of morbidity and mortality worldwide. Cell therapy using mesenchymal stromal cells (MSCs) is an innovative strategy with excessive therapeutic potential in the treatment of sepsis. Staphylococcal enterotoxin B (SEB) preconditioning aims to prolong the interval of survival of transplanted MSCs which induces the production of cytoprotective agents, anti-apoptotic and anti-inflammatory factors. The MSCs were preconditioned with an optimum dose of SEB (470 µmol/L). The expression levels of apoptosis genes and antibacterial activity of MSC and SEB-MSC and their conditioned medium (CM), as well as cell survival, were studied in vitro in an oxidative stress and serum deprivation condition. Following treatment of the septic mice with MSCs and SEB-MSCs, pro/anti-inflammatory cytokines, hematological factors, bacterial clearance and animal survival were assessed. The apoptotic and pro-inflammatory cytokine's genes expression was down-regulated while antibacterial peptides and anti-inflammatory cytokines were up-regulated in SEB-MSC-treated mice. The animal survival rates were improved; bacterial clearance was enhanced in the peritoneal fluids, blood and organs; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were reduced in blood, compared with saline and MSCs alone. This research concludes that transplantation of SEB-MSCs presents improved therapeutic effects on a live bacterial model of sepsis.


Asunto(s)
Enterotoxinas/inmunología , Trasplante de Células Madre Mesenquimatosas/métodos , Células Madre Mesenquimatosas/inmunología , Sepsis/terapia , Animales , Apoptosis , Medios de Cultivo Condicionados , Citocinas/análisis , Citocinas/sangre , Modelos Animales de Enfermedad , Enterotoxinas/farmacología , Masculino , Células Madre Mesenquimatosas/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Sepsis/microbiología
4.
Microb Pathog ; 111: 132-138, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28843722

RESUMEN

Targeted immune therapies are a modern approach to harness the immunity to treat cancer patients. Exosomes (EXOs) are nano-vesicles used for drug delivery in cancer treatment. We aimed to assess the effectiveness of novel designed EXO structures for immunotherapy alone and in combination with other components in animal models. EXO derived from untreated macrophage (EXO), WEHI-164 cell lysate treated EXO (EXOLys), HSP70 enriched WEHI-164 cell lysate treated EXO (EXOHSP70), Naloxone (NLX) treated EXO (EXONLX), Propranolol (PRP) treated EXO (EXOPRP) and staphylococcal enterotoxin B (SEB) anchored to three kinds of EXOs designated as EXO/SEB, EXOLys/SEB, EXOHSP70/SEB were purified from J774 cell line. To determine the therapeutic effect of these novel constructed nano-vesicles, the animals were immunized with different types of EXOs at weekly intervals for three consecutive weeks and in the fourth week the WEHI-164 tumor cells were injected. Finally, the splenocyte proliferation was examined by MTT assay and tumor growth was also determined in each group. We observed that EXOHSP was more effective than EXO and EXOLys to decrease the number of tumor cells and to stimulate immune responses in animal models (P < 0.05). In SEB-anchored EXO group, EXOHSP70/SEB has the potency to stimulate immune responses more efficiently than EXO/SEB and EXOLys/SEB and the tumor was not palpable until 28th day which may refer to synergistic effect of HSP70 and SEB on immunity. In EXONLX treated mice proliferative response decreased significantly compared to control group (P > 0.05) and the tumor number was constant within a period of 28 days and EXOPRP may delay the occurrence of the fibrosarcoma tumor; After development of fibrosarcoma the number of tumors diminished over the studied period of time. Our results demonstrate that HSP70 enriched EXO is an effective immunoadjuvant in cancer immunotherapy and causes tumor regression in animal model.


Asunto(s)
Antineoplásicos/farmacología , Sistemas de Liberación de Medicamentos/métodos , Enterotoxinas/farmacología , Exosomas , Fibrosarcoma/prevención & control , Inmunoterapia/métodos , Macrófagos , Inmunidad Adaptativa , Animales , Antineoplásicos/administración & dosificación , Línea Celular Tumoral/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Fibrosarcoma/patología , Proteínas del Choque Térmico HSP72/farmacología , Inmunización , Irán , Masculino , Ratones , Ratones Endogámicos BALB C , Modelos Animales , Naloxona/farmacología , Vacunación/métodos
5.
Microb Pathog ; 105: 201-210, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28242426

RESUMEN

Outer membrane protein A (OmpA) is the most promising vaccine candidate against one of the most successful nosocomial pathogens, A. baumannii. Despite advantages of the antigen, its cytotoxicity could be considered as a challenge in clinical trials. In order to improve this effective immunogen, rational vaccine design strategies such as structure-based vaccinology should be assessed. However, native structure of OmpA remains controversial. The present study is conducted to address the native structure of OmpA; then, a novel immunogen with lower toxicity and higher antigenicity was designed based on structural vaccinology. Various bioinformatic and immunoinformatic tools were harnessed to perform analyses such as topology, secondary structure, and tertiary structure predictions as well as B-cell epitope predictions. A novel 12-stranded model is suggested for OmpA. K320 and K322 were substituted by Alanine, "NADEEFWN" sequence was replaced by "YKYDFDGVNRGTRGTSEEGTL", Position 1-24 at the N-terminus and the C-terminal sequence "VVQPGQEAAAPAAAQ" were removed. The designed construct has more epitope density and antigenic properties with higher immunogenicity while its cytotoxicity is decreased. Moreover, this single cross-protective antigen could trigger antibodies rendering protection against two important nosocomial pathogens i.e. Pseudomonas aeruginosa and A. baumannii.


Asunto(s)
Acinetobacter baumannii/inmunología , Proteínas de la Membrana Bacteriana Externa/química , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/química , Vacunas Bacterianas/inmunología , Infecciones por Acinetobacter/inmunología , Infecciones por Acinetobacter/prevención & control , Antígenos Bacterianos/química , Antígenos Bacterianos/inmunología , Proteínas de la Membrana Bacteriana Externa/genética , Vacunas Bacterianas/genética , Simulación por Computador , Infección Hospitalaria/inmunología , Infección Hospitalaria/prevención & control , Pruebas Inmunológicas de Citotoxicidad , Epítopos de Linfocito B/inmunología , Inmunogenicidad Vacunal , Conformación Molecular , Pseudomonas aeruginosa/inmunología , Análisis de Secuencia de Proteína , Vacunas Sintéticas/química , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología
6.
Microb Pathog ; 113: 438-444, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29170042

RESUMEN

BACKGROUND: Malignant plasma cells are responsible for Multiple Myeloma (MM). Myeloma Cells (MCs) are located in Bone Marrow (BM) and are in contact with stromal cells. The BM-derived Mesenchymal Stem Cells (BM-MSCs) affect MCs biology through different mechanisms. Currently, Staphylococcal Enterotoxin B (SEB) has been introduced as an anti-tumor agent that is able to kill cancer cells. The present study examined the effects of SEB on MCs and MSCs as an anti-tumor substance. METHODS: U266 cells co-cultured on BM-MSCs and treated with SEB and cell viability was analyzed by MTT assay and flow cytometry. The expression levels of IKKb, IL-6, IL-10, and TGF-ß genes were evaluated by Real Time-PCR technique in U266 cells and BM-MSCs. RESULTS: Data showed that in the presence of SEB, BM-MSCs support U266 cells proliferation and survival. Moreover, SEB, BM-MSCs and BM-MSCs Conditioned Medium (CM) up-regulated IL-6 and IL-10 expression in U266 cells. Additionally, U266 cells showed increased levels in IKKb expression in presence of SEB or BM-MSCs, while expression of IKKb in U266 cells was down-regulated in coexistence of SEB with BM-MSCs or SEB with CM. Also, TGF-ß remained without any changes. DISCUSSION: All in all, SEB can be an appropriate candidate to decrease proliferation and survival rate of cancer cells and it can make noticeable alteration in expression of some genes in U266 cells and BM-MSCs. Further molecular studies are needed to identify the mechanism of action of SEB on U266 cells and BM-MSCs.


Asunto(s)
Antineoplásicos/farmacología , Línea Celular Tumoral/efectos de los fármacos , Enterotoxinas/farmacología , Células Madre Mesenquimatosas/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Medios de Cultivo Condicionados , Expresión Génica/efectos de los fármacos , Humanos , Quinasa I-kappa B/genética , Quinasa I-kappa B/metabolismo , Interleucina-10/genética , Interleucina-10/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Irán , Transducción de Señal/efectos de los fármacos , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismo
7.
Microb Pathog ; 100: 184-194, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27671283

RESUMEN

DNA vaccination -a third generation vaccine-is a modern approach to stimulate humoral and cellular responses against different diseases such as infectious diseases, cancer and autoimmunity. These vaccines are composed of a gene that encodes sequences of a desired protein under control of a proper (eukaryotic or viral) promoter. Immune response following DNA vaccination is influenced by the route and the dose of injection. In addition, antigen presentation following DNA administration has three different mechanisms including antigen presentation by transfected myocytes, transfection of professional antigen presenting cells (APCs) and cross priming. Recently, it has been shown that bacterial toxins and their components can stimulate and enhance immune responses in experimental models. A study demonstrated that DNA fusion vaccine encoding the first domain (DOM) of the Fragment C (FrC) of tetanus neurotoxin (CTN) coupled with tumor antigen sequences is highly immunogenic against colon carcinoma. DNA toxin vaccines against infectious and autoimmune diseases are less studied until now. All in all, this novel approach has shown encouraging results in animal models, but it has to go through adequate clinical trials to ensure its effectiveness in human. However, it has been proven that these vaccines are safe, multifaceted and simple and can be used widely in organisms which may be of advantage to public health in the near future. This paper outlines the mechanism of the action of DNA vaccines and their possible application for targeting infectious diseases, cancer and autoimmunity.


Asunto(s)
Adyuvantes Inmunológicos/genética , Enfermedades Autoinmunes/terapia , Toxinas Bacterianas/genética , Enfermedades Transmisibles/terapia , Neoplasias/terapia , Vacunas de ADN/uso terapéutico , Adyuvantes Inmunológicos/administración & dosificación , Animales , Toxinas Bacterianas/administración & dosificación , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Humanos , Vacunas de ADN/administración & dosificación
8.
Microb Pathog ; 93: 126-30, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26821355

RESUMEN

This study investigated the molecular characterizations of 80 methicillin resistant Staphylococcus epidermidis (MRSE) collected during 2012-2013 in Tehran Children's Medical Center, Iran. About 90% of MRSE isolates were multi-drug resistant (MDR) and the highest resistance was observed to cotrimoxazole and they were quite sensitive to quinupristin-dalfopristin and linezolid. Though vanA gene was not detected, the majority of isolates showed intermediate resistance to vancomycin (MIC90 16 µg/ml). Resistance to mupirocin was observed in 18 isolates. Staphylococcal cassette chromosome mec (SCCmec) types V, III, IV and II were detected in 23.75%, 7.5%, 6.25% and 5% of isolates respectively, in some of which the additional parts of mec or ccr complexes were observed. In 57.5% MRSE isolates SCCmec types were not classified. 41.2% of MRSE isolates were carrying intercellular adhesion (ica) operon and 40% had strong or intermediate biofilm. The types of arginine catabolic mobile element (ACME) were limited to type I and II. Nine sequence types (STs) were seen in mupirocin resistant MRSE isolates. The common STs were ST2, ST5 and ST22 with 27.7% (5/18), 22.2% (4/18) and 16.6% (3/18) frequencies, respectively. ST23, ST54 and ST179 plus three novels STs 580, 581,588 were also observed. The majority of STs, 83.3% (15/18) belonged to clonal complex 2 (CC2). The spread of antibiotic resistance and virulence factors among MRSE species is an alarming sign in Children's Hospitals. The combination of these two issues leads to increase the chance of successfully establishing of common STs in hospital environments, and promotes the device-related infections and bacteremia.


Asunto(s)
Proteínas Bacterianas/genética , Biopelículas/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Staphylococcus aureus Resistente a Meticilina/fisiología , Recombinasas/genética , Infecciones Estafilocócicas/microbiología , Staphylococcus epidermidis/efectos de los fármacos , Antibacterianos/farmacología , Proteínas Bacterianas/metabolismo , Niño , Preescolar , Estudios Transversales , Farmacorresistencia Bacteriana Múltiple , Femenino , Humanos , Lactante , Irán , Masculino , Meticilina/farmacología , Staphylococcus aureus Resistente a Meticilina/clasificación , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Tipificación de Secuencias Multilocus , Operón , Recombinasas/metabolismo , Staphylococcus epidermidis/clasificación , Staphylococcus epidermidis/genética , Staphylococcus epidermidis/fisiología
9.
Appl Microbiol Biotechnol ; 100(6): 2785-95, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26711279

RESUMEN

Botulinum neurotoxin type A (BoNT/A) has been used as an injectable therapeutic agent for the treatment of some abnormal muscle contractions. In this study, TAT(47-57) peptide, a cell-penetrating peptide, was fused with the catalytic domain of BoNT/A for therapeutic purposes. HeLa and BE(2)-C cell lines were treated separately with purified TAT-BoNT/A(1-448) recombinant protein, and transduction of protein was analyzed by western blotting. Also, transcutaneous delivery through mouse skin surface was evaluated by immunohistochemistry. The in vitro catalytic activity of TAT-BoNT/A(1-448) was evaluated by HPLC. The presence of recombinant protein was detected in both of the cell lines as well as mouse skin cryosections after 60 and 120 min of incubation. The concentration of intracellular proteins was increased over time. HPLC analysis showed that this fusion protein has a biological activity 1.5 times as much as the full-length BoNT/A(1-448) protein. TAT-BoNT/A(1-448) fusion protein is biologically active and can transmit through living cells in vitro and in vivo successfully and more effectively compared with BoNT/A(1-448) protein as control.


Asunto(s)
Anticonvulsivantes/metabolismo , Toxinas Botulínicas Tipo A/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Administración Cutánea , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacocinética , Western Blotting , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/genética , Toxinas Botulínicas Tipo A/farmacocinética , Línea Celular , Cromatografía Líquida de Alta Presión , Humanos , Inmunohistoquímica , Ratones , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/farmacocinética
10.
J Mater Sci Mater Med ; 25(2): 363-73, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24186149

RESUMEN

Peripheral nerves are exposed to physical injuries usually caused by trauma that may lead to a significant loss of sensory or motor functions and is considered as a serious health problem for societies today. This study was designed to develop a novel nano bioglass/gelatin conduit (BGGC) for the peripheral nerve regeneration. The bioglass nanoparticles were prepared by sol-gel technique and characterized using transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR) and X-ray diffraction analysis. The interfacial bonding interaction between the nano-bioglass and gelatin in the developed conduits was assessed by FTIR. The surface morphology and pore size of the nanocomposite were investigated through scanning electron microscopy with the pore size of the conduits being 10-40 µm. Biocompatibility was assessed by MTT assay which indicated the BGGC to have good cytocompatibility. The guidance channel was examined and used to regenerate a 10 mm gap in the right sciatic nerve of a male Wistar rat. Twenty rats were randomly divided into two experimental groups, one with the BGGC and the other being normal rats. The gastrocnemius muscle contractility was also examined at one, two and three months post-surgery in all groups using electromyography (EMAP). Histological and functional evaluation and the results obtained from electromyography indicated that at three months, nerve regeneration of the BGGC group was statistically equivalent to the normal group (p > 0.05). Our result suggests that the BGGC can be a suitable candidate for peripheral nerve repair.


Asunto(s)
Cerámica , Gelatina , Nanoestructuras , Regeneración Nerviosa , Nervios Periféricos/fisiología , Microscopía Electrónica , Espectroscopía Infrarroja por Transformada de Fourier , Difracción de Rayos X
11.
Folia Microbiol (Praha) ; 69(1): 145-154, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37924430

RESUMEN

Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are major causes of hospital-acquired infections and sepsis. Due to increasing antibiotic resistance, new treatments are needed. Mesenchymal stem cells (MSCs) have antimicrobial effects, which can be enhanced by preconditioning with antibiotics. This study investigated using antibiotics to strengthen MSCs against MRSA and P. aeruginosa. MSCs were preconditioned with linezolid, vancomycin, meropenem, or cephalosporin. Optimal antibiotic concentrations were determined by assessing MSC survival. Antimicrobial effects were measured by minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and antimicrobial peptide (AMP) gene expression. Optimal antibiotic concentrations for preconditioning MSCs without reducing viability were 1 µg/mL for linezolid, meropenem, and cephalosporin and 2 µg/mL for vancomycin. In MIC assays, MSCs preconditioned with linezolid, vancomycin, meropenem, or cephalosporin inhibited MRSA or P. aeruginosa growth at lower concentrations than non-preconditioned MSCs (p ≤ 0.001). In MBC assays, preconditioned MSCs showed enhanced bacterial clearance compared to non-preconditioned MSCs, especially when linezolid and vancomycin were used against MRSA (p ≤ 0.05). Preconditioned MSCs showed increased expression of genes encoding the antimicrobial peptide genes hepcidin and LL-37 compared to non-preconditioned MSCs. The highest hepcidin expression was seen with linezolid and vancomycin preconditioning (p ≤ 0.001). The highest LL-37 expression was with linezolid preconditioning (p ≤ 0.001). MSCs' preconditioning with linezolid, vancomycin, meropenem, or cephalosporin at optimal concentrations enhances their antimicrobial effects against MRSA and P. aeruginosa without compromising viability. This suggests preconditioned MSCs could be an effective adjuvant treatment for antibiotic-resistant infections. The mechanism may involve upregulation of AMP genes.


Asunto(s)
Células Madre Mesenquimatosas , Staphylococcus aureus Resistente a Meticilina , Infecciones Estafilocócicas , Humanos , Linezolid/farmacología , Linezolid/uso terapéutico , Vancomicina , Pseudomonas aeruginosa/genética , Hepcidinas/farmacología , Hepcidinas/uso terapéutico , Meropenem/farmacología , Meropenem/uso terapéutico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefalosporinas/farmacología , Péptidos Antimicrobianos , Pruebas de Sensibilidad Microbiana , Infecciones Estafilocócicas/microbiología
12.
Front Cell Infect Microbiol ; 14: 1384420, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38756232

RESUMEN

Infectious diseases are among the factors that account for a significant proportion of disease-related deaths worldwide. The primary treatment approach to combat microbial infections is the use of antibiotics. However, the widespread use of these drugs over the past two decades has led to the emergence of resistant microbial species, making the control of microbial infections a serious challenge. One of the most important solutions in the field of combating infectious diseases is the regulation of the host's defense system. Toll-like receptors (TLRs) play a crucial role in the first primary defense against pathogens by identifying harmful endogenous molecules released from dying cells and damaged tissues as well as invading microbial agents. Therefore, they play an important role in communicating and regulating innate and adaptive immunity. Of course, excessive activation of TLRs can lead to disruption of immune homeostasis and increase the risk of inflammatory reactions. Targeting TLR signaling pathways has emerged as a new therapeutic approach for infectious diseases based on host-directed therapy (HDT). In recent years, stem cell-derived exosomes have received significant attention as factors regulating the immune system. The regulation effects of exosomes on the immune system are based on the HDT strategy, which is due to their cargoes. In general, the mechanism of action of stem cell-derived exosomes in HDT is by regulating and modulating immunity, promoting tissue regeneration, and reducing host toxicity. One of their most important cargoes is microRNAs, which have been shown to play a significant role in regulating immunity through TLRs. This review investigates the therapeutic properties of stem cell-derived exosomes in combating infections through the interaction between exosomal microRNAs and Toll-like receptors.


Asunto(s)
Exosomas , MicroARNs , Células Madre , Receptores Toll-Like , Exosomas/metabolismo , Receptores Toll-Like/metabolismo , Humanos , MicroARNs/metabolismo , MicroARNs/genética , Animales , Células Madre/metabolismo , Transducción de Señal , Inmunidad Innata , Enfermedades Transmisibles/inmunología , Enfermedades Transmisibles/metabolismo , Inmunidad Adaptativa
13.
Scand J Infect Dis ; 45(2): 124-30, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22954102

RESUMEN

BACKGROUND: Iran borders 2 high-burden tuberculosis (TB) countries to the east, and has the highest rates of TB in one of its eastern provinces. Limited information is available on the genetic diversity and transmission dynamics of Mycobacterium tuberculosis (MTB) in Iran. To examine the genetic diversity and transmission dynamics of MTB strains we genotyped a collection of isolates from different parts of Iran. METHODS: Standard 15-locus variable number tandem repeat (VNTR) typing was applied to genotype 121 MTB clinical isolates collected from 3 provinces of Iran, including Tehran (the capital of Iran), Sistan-Baluchestan (southeast province of Iran, with the highest rate of TB), and Kermanshah (western part of Iran with high TB/human immunodeficiency virus cases). Antibiotic susceptibility for all isolates was determined using the proportion method. RESULTS: Sixty-six distinct mycobacterial interspersed repetitive unit (MIRU)-VNTR patterns were detected among 121 isolates. Seventy-five strains grouped into 20 clusters, and 46 isolates were unique. The genetic diversity of strains from Sistan-Baluchestan was higher than that in the other provinces. All isolates from Tehran or Kermanshah that grouped into clusters shared identical patterns with Sistan-Baluchestan. The Hunter-Gaston discriminatory index (HGDI) was 0.972, indicating a high power of discrimination for MIRU-VNTR typing. The MIRU 16 and ETRA loci were designated as highly discriminative. The rates of monoresistance and multidrug resistance were 9.9% and 2.4%, respectively. CONCLUSIONS: MIRU-VNTR typing revealed high genetic diversity and suggests the possibility of transmission from Sistan-Baluchestan to other provinces of Iran. This method has potential for genetic analysis and for studying the transmission routes of TB.


Asunto(s)
Secuencias Repetitivas Esparcidas , Repeticiones de Minisatélite , Mycobacterium tuberculosis/genética , Tuberculosis/microbiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Análisis por Conglomerados , Femenino , Variación Genética , Humanos , Irán/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Tipificación Molecular , Mycobacterium tuberculosis/clasificación , Mycobacterium tuberculosis/aislamiento & purificación , Filogenia , Reacción en Cadena de la Polimerasa , Tuberculosis/epidemiología
14.
Res Pharm Sci ; 18(2): 159-176, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36873271

RESUMEN

Background and purpose: Recently, the use of immunotoxins for targeted cancer therapy has been proposed, to find new anticancer drugs with high efficacy on tumor cells with minimal side effects on normal cells. we designed and compared several arazyme (AraA)-based fusion proteins with different ligands to choose the best-targeted therapy for interleukin 13 receptor alpha 2 (IL13Rα2)-overexpressed cancer cells. For this purpose, IL13Rα2 was selected as a receptor and IL13 and IL13.E13K were evaluated as native and mutant ligands, respectively. In addition, Pep-1 and A2b11 were chosen as the peptide ligands for targeted cancer therapy. Experimental approach: Several bioinformatics servers were used for designing constructs and optimization. The structures of the chimeric proteins were predicted and verified by I-TASSER, Q-Mean, ProSA, Ramachandran plot, and Verify3D program. Physicochemical properties, toxicity, and antigenicity were predicted by ProtParam, ToxinPred, and VaxiJen. HawkDock, LigPlot+, and GROMACS software were used for docking and molecular dynamics simulation of the ligand-receptor interaction. Findings/Results: The in silico results showed AraA-A2b11 has higher values of confidence score and Q-mean score was obtained for high-resolution crystal structures. All chimeric proteins were stable, non-toxic, and non-antigenic. AraA-(A(EAAAK)4ALEA(EAAAK)4A)2-IL13 retained its natural structure and based on ligand-receptor docking and molecular dynamic analysis, the binding ability of AraA-(A(EAAAK)4ALEA(EAAAK)4A)2-IL13 to IL13Rα2 was sufficiently strong. Conclusion and implications: Based on the bioinformatics result AraA-(A(EAAAK)4ALEA(EAAAK)4A)2-IL13 was a stable fusion protein with two separate domains and high affinity with the IL13Rα2 receptor. Therefore, AraA-(A(EAAAK)4ALEA(EAAAK)4A)2-IL13 fusion protein could be a new potent candidate for target cancer therapy.

15.
Toxicol In Vitro ; 92: 105651, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37482138

RESUMEN

Targeting cell surface receptors with immunotoxins provides a novel, unique and highly potent treatment against cancers. A high expression of interleukin-13 (IL13) receptor α2 (IL13Rα2) has been reported in different types of cancers including glioblastoma multiforme (GBM). In this paper, to target IL13Rα2 on GBM cells, a fusion protein was generated comprising human IL13 and staphylococcal enterotoxin B (SEB), termed IL13-linker-SEB. The fusion protein was cloned into pET28a(+) and expressed in Escherichia coli strain BL21 (DE3); U251 (IL13Rα2-positive) and T98G (IL13Rα2-negative) GBM cell lines were employed and the functional activity of IL13-linker-SEB was evaluated by cell ELISA, cytotoxicity (MTT and LDH), apoptosis (flow cytometry and caspase-3 activity), adhesion, scratch and RT-PCR tests. SEB and chemotherapeutic drugs were employed to be compared to IL13-linker-SEB function. The IL13-linker-SEB exhibited higher binding affinity and cytotoxicity compared to SEB on U251 cells, although both recombinant proteins had shown similar behavior regarding T98G cells. Furthermore, the highest induction of apoptosis was observed in U251 cells treated with IL13-linker-SEB which was confirmed by Bax/Bcl-2 ratio. The expression of MMP2, MMP9 and VEGFR2 in U251 cells experienced a significant reduction after treatment with IL13-linker-SEB compared to SEB and T98G treated cells. The data showed that IL13-linker-SEB can be considered as a novel potential agent for GBM treatment; however, further research is needed to investigate the efficacy.


Asunto(s)
Glioblastoma , Subunidad alfa2 del Receptor de Interleucina-13 , Humanos , Glioblastoma/tratamiento farmacológico , Glioblastoma/metabolismo , Interleucina-13/genética , Interleucina-13/farmacología , Interleucina-13/metabolismo , Subunidad alfa2 del Receptor de Interleucina-13/genética , Subunidad alfa2 del Receptor de Interleucina-13/metabolismo , Subunidad alfa2 del Receptor de Interleucina-13/uso terapéutico , Proteínas Recombinantes
16.
Trials ; 24(1): 442, 2023 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-37408032

RESUMEN

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has been shown to affect nutritional recommendations. Some functional foods have been demonstrated to be useful in the treatment of people with COVID-19. However, little is known about the impact of combining functional foods on disease control. This study aimed to investigate the effects of functional foods mixture on serum levels of inflammatory cytokines and biochemical findings in patients with COVID-19. METHODS: A randomized double-blind controlled trial was conducted in Baqiyatallah Al-Azam hospital in Tehran, Iran. Sixty patients were randomly assigned to receive either a soup containing functional foods (n = 30) or a usual soup (control group) (n = 30). Participants' sociodemographic information was gathered using a general questionnaire. Blood levels of inflammatory markers and biochemical findings were assessed using standard protocols. RESULTS: The results showed that soup containing functional foods was more effective in controlling serum levels of D-dimer, blood urea nitrogen, and creatinine than the control group (P < 0.05). Also, more significant improvement was found in the intervention group vs control group in terms of interleukin (IL)-1ß, IL-6, IL-17, IL-10, and tumor necrose factor-α (P < 0.05). In contrast, the control intervention more efficiently controlled potassium levels and reduced quantitative C-reactive protein than the intervention group (P < 0.05). CONCLUSIONS: This study indicates a soup containing functional foods could alleviate biomarkers of inflammation in patients with COVID-19. However, its effectiveness on biochemical findings remained inconclusive which warranted further research. TRIAL REGISTRATION: IRCT, IRCT20180201038585N11. Registered 23 August 2021, https://www.irct.ir/trial/57338.


Asunto(s)
COVID-19 , Humanos , SARS-CoV-2 , Alimentos Funcionales , Citocinas , Irán , Método Doble Ciego , Resultado del Tratamiento
17.
J Mater Sci Mater Med ; 23(11): 2783-92, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22826004

RESUMEN

Bioactive glass has been investigated for variety of tissue engineering applications. In this study, fabrication, in vitro and in vivo evaluation of bioactive glass nanocomposite scaffold were investigated. The nanocomposite scaffolds with compositions based on gelatin and bioactive glass nanoparticles were prepared. The apatite formation at the surface of the nanocomposite samples confirmed by Fourier transform infrared spectroscopy, scanning electron microscopy and X-ray powder diffraction analyses. The in vitro characteristics of bioactive glass scaffold as well as the in vivo bone formation capacity of the bioactive glass scaffold in rabbit ulnar model were investigated. The bioactive glass scaffold showed no cytotoxicity effects in vitro. The nanocomposite scaffold made from gelatin and bioactive glass nanoparticles could be deliberated as an extremely bioactive and prospective bone tissue engineering implant. Bioactive glass scaffolds were capable of guiding bone formation in a rabbit ulnar critical-sized-defect model. Radiographic evaluation indicated that successful bridging of the critical-sized defect on the sides both next to and away from the radius took place using bioactive glass scaffolds. X-ray analysis also proposed that bioactive glass scaffolds supported normal bone formation via intramembranous formation.


Asunto(s)
Regeneración Ósea , Gelatina , Vidrio , Nanotecnología , Andamios del Tejido , Cúbito/fisiología , Animales , Ensayo de Inmunoadsorción Enzimática , Microscopía Electrónica de Rastreo , Microscopía Electrónica de Transmisión , Difracción de Polvo , Conejos , Espectroscopía Infrarroja por Transformada de Fourier
18.
Curr Pharm Biotechnol ; 23(6): 803-817, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34825639

RESUMEN

INTRODUCTION: Hepatitis B and C viruses are one of the leading causes of health problems in the world and early diagnosis and treatment of them are very important. Thereby, this study aimed to evaluate the validity and reliability of usable diagnostic tests for the detection of hepatitis B and C viruses in the clinical setting and to compare them with each other. MATERIALS AND METHODS: In this review article, we have searched major online databases, including PubMed and EMBASE. 42 retrieved articles were published between January 2000 and January 2020, which are summarized in this review. RESULTS: Immunoassay approaches are general techniques for the identification of pathogenic agents, among which ELISA is the gold standard for the detection of HBsAg. While serological techniques are not conclusive, molecular assays are really important because of the high sensitivity to detect chronic hepatitis B without HBeAg, in which viral loads are very low. Biosensors have more elevated selectivity and sensitivity and faster responses compared to other methods. CONCLUSION: This study suggests that all of the molecular, serological, and biotechnological assays have advantages and disadvantages for diagnosing hepatitis B and C viruses which are dependent on the condition, so we should choose one of them in regards to the time, cost, and laboratory equipment along with the clinical symptoms.


Asunto(s)
Virus de la Hepatitis B , Hepatitis B , Hepatitis B/diagnóstico , Antígenos de Superficie de la Hepatitis B/análisis , Virus de la Hepatitis B/genética , Humanos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
19.
Probiotics Antimicrob Proteins ; 14(2): 224-237, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35031968

RESUMEN

Probiotics are living microorganisms that have favorable effects on human and animal health. The most usual types of microorganisms recruited as probiotics are lactic acid bacteria (LAB) and bifidobacteria. To date, numerous utilizations of probiotics have been reported. In this paper, it is suggested that probiotic bacteria can be recruited to remove and degrade different types of toxins such as mycotoxins and algal toxins that damage host tissues and the immune system causing local and systemic infections. These microorganisms can remove toxins by disrupting, changing the permeability of the plasma membrane, producing metabolites, inhibiting the protein translation, hindering the binding to GTP binding proteins to GM1 receptors, or by preventing the interaction between toxins and adhesions. Here, we intend to review the mechanisms that probiotic bacteria use to eliminate and degrade microbial toxins.


Asunto(s)
Micotoxinas , Probióticos , Animales , Bacterias/metabolismo , Bifidobacterium , Sistema Inmunológico/microbiología , Micotoxinas/metabolismo
20.
Ir J Med Sci ; 191(4): 1751-1758, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34528185

RESUMEN

INTRODUCTION: Given the many misconceptions in terms of both diagnosis and treatment, SARS-CoV-2 continues to infect and victimize. Notwithstanding molecular testing is the gold standard method of in vitro diagnostic, the often long-waiting time, as well as false-negative results are daunting challenges facing us. In this study, we aimed to report the diagnostic value of laboratory findings in COVID-19 patients, with an extensive focus on the differences between PCR-positive and PCR-negative cases. PATIENTS AND METHODS: We did a retrospective single-centre study on a large cohort of 1546 COVID-19 patients in Tehran, Iran. Based on clinical symptoms, chest CTs were performed for all the patients. Also, molecular testing of swab specimens was also performed for 1450 cases. RESULTS: All the data on laboratory results were retrospectively extracted from medical records. Of the 1546 patients, 1040 (67.5%) were male and 506 (32.5%) were female with the mean age of 55.67. On admission, 31.4% of the whole study population displayed lymphopenia and 38.9% showed neutrophilia. Decreased hemoglobin and mild thrombocytopenia were also found in 40% and 18.6% of cases, respectively. Elevated lactate dehydrogenase in nearly 75% of COVID-19 cases was the most common alteration amongst biochemical parameters which together with increased ESR and CRP could serve as diagnostic markers in SARS-CoV-2 infection. Of the 1450 patients with a PCR result, 439 (28.3%) were PCR-negative and 1011 (65.3%) were PCR-positive. Notably, lymphopenia and increased AST were higher in the PCR-positive group than their negative counterparts. Albeit being in the normal range, a significant decrease in the number of monocytes was also evident in the PCR-positive cases. CONCLUSIONS: As far we are aware, this is the first time that we reported a comprehensive exploration of laboratory characteristics of a large cohort of hospitalized COVID-19 patients from Iran, hoping that these data will cast more light on the diagnostic significance of these parameters.


Asunto(s)
COVID-19 , Linfopenia , COVID-19/diagnóstico , Femenino , Humanos , Irán/epidemiología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos , SARS-CoV-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA